These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 30853366)

  • 21. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
    PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
    Vega-Olivo M; Criner GJ
    Nurse Pract; 2018 May; 43(5):48-54. PubMed ID: 29465476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis.
    Enomoto N; Oyama Y; Enomoto Y; Yasui H; Karayama M; Kono M; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
    Chron Respir Dis; 2019; 16():1479972318809476. PubMed ID: 30380910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
    Raghu G; Wells AU; Nicholson AG; Richeldi L; Flaherty KR; Le Maulf F; Stowasser S; Schlenker-Herceg R; Hansell DM
    Am J Respir Crit Care Med; 2017 Jan; 195(1):78-85. PubMed ID: 27331880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches.
    Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; Kasselman LJ; Glass AD; DeLeon J; Reiss AB
    Respir Investig; 2020 Sep; 58(5):320-335. PubMed ID: 32487481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
    Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
    Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
    Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
    Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Idiopathic pulmonary fibrosis--a case report].
    Munteanu O
    Pneumologia; 2010; 59(3):158-63. PubMed ID: 21058469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
    Jo HE; Randhawa S; Corte TJ; Moodley Y
    Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.